EMA issues additional guidance on active substance master file procedure
This article was originally published in SRA
Executive Summary
The European Medicines Agency has issued additional guidance on how drug companies should prepare their active substance master files (ASMFs) to ensure EU competent authorities are able to identify and track where the same file is being used in multiple drug evaluation procedures1.